Past Presentations
-
A Novel EEV-Conjugated PMO, ENTR-701, Reduces Nuclear Foci and Corrects Aberrant Splicing in Myotonic Dystrophy Type 1 Preclinical Models
- By: Amy Hicks, PhD, Principal Scientist, Entrada Therapeutics
- At: 2022 New Directions in Biology and Disease of Skeletal Muscle Conference
DownloadJun 20, 2022 -
Development of ENTR-601-44, a Novel EEV-Conjugated PMO for Duchenne Muscular Dystrophy
- By: Nelsa Estrella, PhD, Principal Scientist, Entrada Therapeutics
- At: 2022 New Directions in Biology and Disease of Skeletal Muscle Conference
DownloadJun 20, 2022 -
Development of Endosomal Escape Vehicles to Enhance the Intracellular Delivery of Oligonucleotides
- By: Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: 27th American Peptide Symposium
DownloadJun 13, 2022 -
Exon Skipping and Read Through Agents Panel
- By: Nerissa Kreher, MD, Chief Medical Officer, Entrada Therapeutics
- At: CureDuchenne FUTURES 2022 Conference
DownloadMay 28, 2022 -
Development of Endosomal Escape Vehicles to Enhance the Intracellular Delivery of Oligonucleotides
- By: Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
DownloadMay 16, 2022 -
Endosomal Escape Vehicle (EEV)-Conjugation Enhances Functional Delivery of Oligonucleotides
- By: Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: TIDES USA: Oligonucleotide & Peptide Therapeutics
DownloadMay 11, 2022 -
Enhanced Exon Skipping and Dystrophin Production in a Mouse Model of Duchenne Muscular Dystrophy with EEV-PMO Treatment
- By: Mahasweta Girgenrath, PhD, Head of Cardiovascular and Neuromuscular Therapeutic Areas, Entrada Therapeutics
- At: 2022 MDA Clinical and Scientific Conference
DownloadMar 16, 2022